Table 2.
Patient characteristics.
| Variable | Development cohort n = 3839 | Validation cohort n = 960 | ||||
|---|---|---|---|---|---|---|
| CsPCa n = 1607 (41.9%) | Non-CsPCa n = 2232 (58.1%) | p-value | CsPCa n = 394 (41.1%) | Non-CsPCa n = 566 (58.9%) | p-value | |
| Age | 71 (65,76) | 66 (60,71) | < 0.001 | 70 (65,77) | 66 (61,72) | < 0.001 |
| PSA | 8.0 (5.6,13.5) | 6.3 (4.7,9.0) | < 0.001 | 8.7 (5.7 14.9) | 6.2 (4.5,9.0) | < 0.001 |
| PV | 45 (34, 62) | 62 (44,85) | < 0.001 | 47 (35,65) | 64 (46,86) | < 0.001 |
| PSAD | 0.18 (0.12,0.32) | 0.10 (0.07,0.16) | < 0.001 | 0.19 (0.12,0.33) | 0.10 (0.07,0.15) | < 0.001 |
| DRE (suspicious) | 699 (43.5%) | 368 (16.5%) | < 0.001 | 186 (47.2%) | 99 (17.5%) | < 0.001 |
| FH (yes) | 125 (7.8%) | 148 (6.6%) | 0.172 | 36 (9.1%) | 32 (5.7%) | 0.038 |
| PNB (yes) | 392 (24.4%) | 768 (34.4%) | < 0.001 | 87 (22.1%) | 205 (36.2%) | < 0.001 |
| PI-RADS | < 0.001 | < 0.001 | ||||
| 1 | 51(3.2%) | 393 (17.6%) | 9 (2.3%) | 96 (17.0%) | ||
| 2 | 21 (1.3%) | 117 (5.2%) | 2 (0.5%) | 28 (4.9%) | ||
| 3 | 163 (10.1%) | 801 (35.9%) | 36 (9.1%) | 207 (36.6%) | ||
| 4 | 746 (46.4%) | 782 (35.0%) | 190 (48.2%) | 207 (36.6%) | ||
| 5 | 626 (39.0%) | 139 (6.3%) | 157 (39.9%) | 28 (4.9%) | < 0.001 | |
CsPCa clinically significant prostate cancer, PSA prostate specific antigen, PV prostate volume, PSAD PSA density, DRE digital rectal exam findings, FH family history of PCa. PNB previous negative biopsy.